Marker Therapeutics Inc (MRKR)

[microcapbiotech]

"The Company believes that its existing cash, cash equivalents and restricted cash will fund its operating expenses and capital expenditure requirements into the first quarter of 2023."
Question is can they hold out on doing a dilution and hope for good data readout before the end of 2022?
At least if that happens, they can at least do a dilution at hopefully a much higher price.